SANGAMO THERAPEU

SGMO NASDAQ
11.02
-0.42
-3.67%
盘后: 11.17 +0.15 +1.36% 17:46 08/23 EDT
开盘
11.35
昨收
11.44
最高
11.65
最低
10.96
成交量
109.14万
成交均量(3M)
172.28万
52周最高
19.25
52周最低
6.26
换手率
0.94%
市值
12.75亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供SANGAMO THERAPEU SGMO股票价格,SANGAMO THERAPEU股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
展开 >

最近浏览

名称
价格
涨跌幅